| abstract |
Claim 1: Antibody-active ingredient conjugates (ADCs) characterized in that it has the formula (1) wherein n represents 1 to 8; AK represents an anti-CD123 antibody, selected from the group consisting of TPP-8987, TPP-9476 and TPP-8988, or AK represents an anti-CXCR5 antibody, preferably selected from the group consisting of TPP-9574, TPP-9580 and TPP- 9024, or AK represents one of its antibody antigen-binding fragments, wherein the antibody or antigen-binding fragment is linked through a sulfur atom of a cysteine side group; as well as its salts, solvates and salts of these solvates. Claim 7: Pharmaceutical composition comprising at least one antibody-active ingredient (ADC) conjugate according to one or more of the preceding claims characterized in that it is in combination with an inert, non-toxic, pharmaceutically appropriate excipient. Claim 11: Antibody-active ingredient (ADCs) conjugates according to one or more of the preceding claims characterized in that they are for use in a method for the treatment of cancer and tumors in combination with one or more therapeutic preparations for cancer immunotherapy. or with one or more active ingredients aimed at a molecular target of cancer immunotherapy. |